239 related articles for article (PubMed ID: 23127572)
1. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
Xu KF; Zhang P; Tian X; Ma A; Li X; Zhou J; Zeng N; Gui YS; Guo Z; Feng R; Zhang W; Sun W; Cai B
Respir Med; 2013 Feb; 107(2):263-8. PubMed ID: 23127572
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
3. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.
Young LR; Vandyke R; Gulleman PM; Inoue Y; Brown KK; Schmidt LS; Linehan WM; Hajjar F; Kinder BW; Trapnell BC; Bissler JJ; Franz DN; McCormack FX
Chest; 2010 Sep; 138(3):674-81. PubMed ID: 20382711
[TBL] [Abstract][Full Text] [Related]
5. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
6. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
8. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
Koba T; Arai T; Kitaichi M; Kasai T; Hirose M; Tachibana K; Sugimoto C; Akira M; Hayashi S; Inoue Y
Respirology; 2018 Mar; 23(3):331-338. PubMed ID: 28960664
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
Chang WY; Cane JL; Blakey JD; Kumaran M; Pointon KS; Johnson SR
Respir Res; 2012 Apr; 13(1):34. PubMed ID: 22513045
[TBL] [Abstract][Full Text] [Related]
12. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.
Radzikowska E; Jaguś P; Skoczylas A; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Pol Arch Med Wewn; 2013; 123(10):533-8. PubMed ID: 24060688
[TBL] [Abstract][Full Text] [Related]
13. Involvement of lymphatics in lymphangioleiomyomatosis.
Glasgow CG; Taveira-DaSilva A; Pacheco-Rodriguez G; Steagall WK; Tsukada K; Cai X; El-Chemaly S; Moss J
Lymphat Res Biol; 2009 Dec; 7(4):221-8. PubMed ID: 20143921
[TBL] [Abstract][Full Text] [Related]
14. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Shawker T; Glasgow CG; Stylianou M; Moss J
Chest; 2015 Oct; 148(4):1027-1033. PubMed ID: 26066372
[TBL] [Abstract][Full Text] [Related]
15. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
17. Lymphangioleiomyomatosis: differential diagnosis and optimal management.
Xu KF; Lo BH
Ther Clin Risk Manag; 2014; 10():691-700. PubMed ID: 25187723
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
19. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].
Sobiecka M
Wiad Lek; 2016; 69(2 Pt 1):123-9. PubMed ID: 27421126
[TBL] [Abstract][Full Text] [Related]
20. The role of moesin in diagnosing and assessing severity of lymphangioleiomyomatosis.
Song X; Cai H; Peng W; Chen K; Abuduxukuer Z; Zeng Y; Zhu G; Lu C; Chen Y; Wang J; Ye L; Jin M
Respir Res; 2024 Jan; 25(1):57. PubMed ID: 38267973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
